Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics
Abemaciclib is an oral anticancer drug that inhibits cyclin dependent kinases 4 and 6 and is metabolized by cytochrome P450 3A in the intestines and liver to active metabolites. The objectives were (1) to develop a mechanistic model to characterize the pharmacokinetics (PK) of the active moieties an...
Saved in:
Main Authors: | Emmanuel Chigutsa (Author), Siva Rama Prasad Kambhampati (Author), Amanda Karen Sykes (Author), Maria M. Posada (Author), Jan‐Stefan van derWalt (Author), P. Kellie Turner (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Abemaciclib does not increase the corrected QT interval in healthy participants
by: Jill C. Chappell, et al.
Published: (2023) -
Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
by: Sen Sun, et al.
Published: (2022) -
Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023) -
Mechanistic Computational Models of Epithelial Cell Transporters-the Adorned Heroes of Pharmacokinetics
by: Jasia King, et al.
Published: (2021) -
Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer
by: David J. Kurtyka, MS, et al.
Published: (2021)